<DOC>
	<DOCNO>NCT01694875</DOCNO>
	<brief_summary>The objective clinical study evaluate AHPV-GT Assay use PANTHER System cervical cancer screening . This objective accomplish ASC-US Study evaluate performance characteristic AHPV-GT Assay use PANTHER System sample population woman ASC-US Pap test result 21 year age old ( `` ≥21 year age '' ) time Pap visit . For Adjunct Study , objective accomplish evaluate ability AHPV-GT Assay use PANTHER System identify woman increase risk cervical disease sample population woman negative ( NILM ) cytology result ≥30 year age time Pap visit .</brief_summary>
	<brief_title>Clinical Evaluation APTIMA® HPV 16 18/45 Genotype Assay PANTHER® System</brief_title>
	<detailed_description />
	<mesh_term>Papillomavirus Infections</mesh_term>
	<criteria>Subjects previously enrol prospective , multicenter US clinical study APTIMA HPV Assay TIGRIS System ( protocol 2007HPVASCUS30 ) eligible inclusion study AHPVGT Assay use PANTHER System describe protocol . All evaluable ASCUS Study subject ≥21 year age eligible inclusion . Evaluable Adjunct Study subject ≥30 year age eligible follow criterion meet : subject attend colposcopy visit , subject attend colposcopy visit referral Pap sample positive APTIMA HPV Assay result APTIMA HPV Assay TIGRIS System study ( protocol 2007HPVASCUS30 ) APTIMA HPV Assay PANTHER System study ( protocol AHPVPSUS11003 ) . Eligible subject exclude evaluable sample . This may due insufficient volume sample deem unsuitable testing ( eg , store unacceptable condition ) .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>cervix cancer</keyword>
	<keyword>HPV</keyword>
	<keyword>APTIMA</keyword>
</DOC>